Nebenwirkungen · Mixtard
Mixtard 30 40 international units/ml suspension for injection in vial. Mixtard 30 100 international units/ml suspension for injection in vial. Mixtard 30 Penfill 100 international units/ml suspension for injection in cartridge. Mixtard 30 InnoLet 100 international units/ml suspension for injection in pre-filled pen. Mixtard 30 FlexPen 100 international units/ml suspension for injection in pre-filled pen. · Abschnitt 4.8 · PDF-Seite 7
HOS-111165 · Präparat HOS-093463
The adverse reactions listed below are based on clinical trial data and classified according to MedDRA frequency and System Organ Class. Frequency categories are defined according to the following convention: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-01-24T16:35:00Z · SHA-256 6f5b0cbd7924d3f8fc676646a82c37907875f834271b75ee6e7920db1e310786 · Passage a9e03c38cc4173dde7ecd4555481735ff29a2542e215f7a07fe3b766ad66c0df · Zeichen 1001–1405 im Abschnitt